By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
At Amgen, our mission is to serve patients. As a science-based, patient-focused organization, we discover and develop innovative therapies to treat serious illnesses. Our medicines have made a dramatic difference in the lives of millions.
For the up-to-date Summary of Product Characteristics (SmPC) and the package leaflet, please visit the medicines information database on the website of the Medicines Evaluation Board: www.geneesmiddeleninformatiebank.nl
What diseases is it used for?
AMGEVITA is used in the treatment of the following inflammatory diseases:
How does it work?
The active substance in AMGEVITA, adalimumab, binds to a specific protein (tumor necrosis factor or TNFα), which is present at increased levels in various inflammatory diseases such as those mentioned above. The binding causes reduced disease activity.
How is it administered?
AMGEVITA is injected subcutaneously (under the skin).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What it is used for
Aranesp is used to treat:
Anemia occurs when the blood does not contain enough red blood cells, with symptoms including fatigue, weakness and shortness of breath.
How does it work?
The active substance in Aranesp, darbepoetin alpha, works in the same way as the naturally occurring hormone erythropoietin (or EPO). Erythropoietin is produced in the kidneys and prompts the bone marrow to produce more red blood cells.
How is it administered?
Aranesp is injected subcutaneously (under the skin) or during dialysis administered intravenously (via the dialysis line).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
BLINCYTO is used to treat acute lymphoblastic leukemia (ALL):
In adults with recurring ALL or with ALL that has not responded to previous treatment (also called 'relapsed/refractory acute lymphoblastic leukemia')
In adults who have a small number of cancer cells left after the previous treatment (also called 'minimal residual disease')
In children (≥1 year), teenagers, and young adults for whom previous treatments have not worked or no longer work
Acute lymphoblastic leukemia is a type of blood cancer in which a certain type of white blood cells, the B lymphocytes, proliferate.
How does it work?
The active substance in BLINCYTO, blinatumomab, works by allowing the immune system to attack and destroy these abnormal white blood cancer cells.
How is it administered?
BLINCYTO is administered intravenously (by infusion).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
IMLYGIC is used to treat adult patients with a type of skin cancer called 'melanoma', which has spread to the skin or lymph nodes, for whom surgery is not possible.
How does it work?
The active substance in IMLYGIC, talimogene laherparepvec, is an attenuated form of herpes simplex virus type 1 (HSV-1), commonly known as cold sore virus. This virus has been altered in such a way that it multiplies more effectively in tumors than in normal cells. This leads to destruction of tumor cells infected by the virus.
How is it administered?
IMLYGIC is injected into the tumor through the skin (always by a healthcare professional).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
Kyprolis, in combination with other medicines, is used to treat adult patients with multiple myeloma who have previously received at least one other treatment for this disease.
Multiple myeloma, also known as Kahler's disease, is a type of plasma cell cancer (plasma cells are a type of white blood cell).
How does it work?
The active substance in Kyprolis, carfilzomib, works by blocking the proteasome. The proteasome is a system in the cells that breaks down proteins when they are damaged or no longer needed. By inhibiting the breakdown of proteins in cancer cells, which often contain more abnormal proteins, Kyprolis causes the death of cancer cells.
How is it administered?
Kyprolis is given intravenously (by infusion), always in combination with other medicines used to treat multiple myeloma.
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
Mimpara is used for:
In primary and secondary hyperparathyroidism, too much parathyroid hormone is produced by the parathyroid glands. This can cause calcium loss in the bones.
How does it work?
The active substance in Mimpara, cinacalcet, works by controlling parathyroid hormone (PTH), calcium, and phosphate levels in your body.
How is it administered?
Mimpara is taken orally (by mouth) as a tablet or as a granular powder mixture.
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
MVASI is used in the treatment of various types of cancer such as:
How does it work?
The active substance in MVASI, bevacizumab, binds to vascular endothelial growth factor (VEGF), thereby inhibiting the binding of VEGF to the receptors on the surface of endothelial cells. It inhibits the formation of blood vessels in tumors and thus tumor growth.
How is it administered?
MVASI is administered intravenously (by infusion).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What is it used for?
Neulasta is used to treat neutropenia due to cytotoxic chemotherapy.
Neutropenia is a deficiency of white blood cells. The white blood cells are important because they help the body fight infections. These cells are very sensitive to the effects of chemotherapy, which can reduce the number of these cells in the body, increasing the risk of infections.
How does it work?
The active substance in Neulasta, pegfilgrastim, is a protein belonging to a group of proteins called 'cytokines', which is very similar to a body's own protein (granulocyte colony stimulating factor) that stimulates the bone marrow to produce more white blood cells that help the body fight infection.
How is it administered?
Neulasta is injected subcutaneously (under the skin).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What is it used for?
Neupogen can be used:
How does it work?
The active substance in Neupogen, filgrastim, is a protein belonging to a group of proteins called "cytokines", which is very similar to a body's own protein (granulocyte colony stimulating factor) that stimulates the bone marrow to produce more white blood cells that help the body fight infection.
How is it administered?
Neupogen is injected subcutaneously (under the skin) or given intravenously (by infusion).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
Nplate is used to treat:
* Immune-mediated thrombocytopenia (ITP) in adults who do not respond to other treatments (e.g. corticosteroids and immunoglobulins).
* Chronic ITP in children aged ≥ 1 year who do not respond to other treatments (e.g. corticosteroids and immunoglobulins).
In the blood, platelets help close wounds and form blood clots. ITP is a disease in which the body's immune system destroys its own platelets and thus a shortage of platelets occurs. Very low platelet counts can cause bruising and severe bleeding.
How does it work?
The active substance in Nplate, romiplostim, is a protein that stimulates bone marrow (part of the bone that makes blood cells) to produce more platelets.
How is it administered?
Nplate is injected subcutaneously (under the skin).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
Otezla is used to treat adults with:
How does it work?
The active substance in Otezla, apremilast, inhibits phosphodiesterase-4 (PDE-4) in inflammatory cells, thereby limiting the inflammatory response and reducing inflammation.
How is it administered?
Otezla is taken orally (by mouth) as a tablet.
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
Parsabiv is used to treat excessive secretion of parathyroid hormone (secondary hyperparathyroidism) in patients with poor kidney function who require dialysis to remove waste from their blood.
In secondary hyperparathyroidism, the parathyroid glands (four small glands in the neck) produce too much parathyroid hormone (PTH). This excess of PTH can cause loss of calcium from the bones, which can lead to bone pain and fractures and problems with blood and heart vessels.
How does it work?
The active substance in Parsabiv, etelcalcetide, reduces the amount of parathyroid hormone (PTH) and thus helps regulate the amount of calcium in the body.
How is it administered?
Parsabiv is given by a doctor or nurse at the end of your hemodialysis treatment through the tube (bloodline) that connects you to the hemodialysis machine.
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
Prolia is used to treat:
How does it work?
The active substance in Prolia, denosumab, is a protein (monoclonal antibody) that interferes with the action of another protein with the aim of treating bone loss and osteoporosis. Treatment with Prolia makes the bone stronger so that it is less likely to break.
How is it administered?
Prolia is injected subcutaneously (under the skin).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
Repatha is used to lower cholesterol.
Repatha is used in the following patient groups:
How does it work?
The active substance in Repatha, evolocumab, is a protein that attaches specifically to a substance in the body called PCSK9. By binding PCSK9, the liver is better able to remove cholesterol from the blood. In this way, the risk of heart attacks and strokes, among other things, is reduced.
How is it administered?
Repatha is injected subcutaneously (under the skin).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What diseases is it used for?
Vectibix is used to treat metastatic colorectal cancer in adult patients with a type of tumor known as 'Wild-type RAS tumor'. It is used alone or in combination with other cancer medicines.
How does it work?
The active substance in Vectibix, panitumumab, specifically recognizes and attaches to the epidermal growth factor receptor (EGFR), which is found on the surface of some tumor cells. When growth factors (the body's own proteins) attach to the EGFR, the tumor cell is stimulated to grow and divide. Panitumumab attaches to the EGFR and thus prevents the tumor cell from receiving messages required for growth and division.
How is it administered?
Vectibix is given intravenously (by infusion).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.
What is it used for?
XGEVA is used in the following cases:
How does it work?
The active substance in XGEVA, denosumab, is a protein (monoclonal antibody) that works by slowing down bone breakdown caused by the spread of cancer to the bone or by a giant cell tumor of the bone.
How is it administered?
XGEVA is injected subcutaneously (under the skin).
Source: Patient Information Leaflets, Amgen. See www.geneesmiddeleninformatiebank.nl for the most recent version.